Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
19 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Sagetis Biotech, S.L. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Sagetis Biotech, S.L. - Product Pipeline Review - 2014', provides an overview of the Sagetis Biotech, S.L.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sagetis Biotech, S.L.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sagetis Biotech, S.L. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sagetis Biotech, S.L.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sagetis Biotech, S.L.'s pipeline products Reasons to buy - Evaluate Sagetis Biotech, S.L.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sagetis Biotech, S.L. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sagetis Biotech, S.L.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sagetis Biotech, S.L. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sagetis Biotech, S.L. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Sagetis Biotech, S.L. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Sagetis Biotech, S.L. Snapshot 4 Sagetis Biotech, S.L. Overview 4 Key Information 4 Key Facts 4 Sagetis Biotech, S.L. - Research and Development Overview 5 Key Therapeutic Areas 5 Sagetis Biotech, S.L. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Sagetis Biotech, S.L. - Pipeline Products Glance 9 Sagetis Biotech, S.L. - Early Stage Pipeline Products 9 Preclinical Products/Combination Treatment Modalities 9 Sagetis Biotech, S.L. - Drug Profiles 10 Gene Therapy for Lysosomal Storage Disease 10 Product Description 10 Mechanism of Action 10 R&D Progress 10 SAG-001 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 SAG-002 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 SAG-003 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Sagetis Biotech, S.L. - Pipeline Analysis 14 Sagetis Biotech, S.L. - Pipeline Products by Target 14 Sagetis Biotech, S.L. - Pipeline Products by Molecule Type 15 Sagetis Biotech, S.L. - Pipeline Products by Mechanism of Action 16 Sagetis Biotech, S.L. - Locations And Subsidiaries 17 Head Office 17 Appendix 18 Methodology 18 Coverage 18 Secondary Research 18 Primary Research 18 Expert Panel Validation 18 Contact Us 19 Disclaimer 19
List of Tables Sagetis Biotech, S.L., Key Information 4 Sagetis Biotech, S.L., Key Facts 4 Sagetis Biotech, S.L. - Pipeline by Indication, 2014 6 Sagetis Biotech, S.L. - Pipeline by Stage of Development, 2014 7 Sagetis Biotech, S.L. - Monotherapy Products in Pipeline, 2014 8 Sagetis Biotech, S.L. - Preclinical, 2014 9 Sagetis Biotech, S.L. - Pipeline by Target, 2014 14 Sagetis Biotech, S.L. - Pipeline by Molecule Type, 2014 15 Sagetis Biotech, S.L. - Pipeline Products by Mechanism of Action, 2014 16
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.